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Summary
Background—Red blood cell (RBC) variants protect African children from severe Plasmodium 
falciparum malaria. Their individual and interactive impacts on mild disease and parasite density, 
and their modification by age-dependent immunity, are poorly understood.
Methods—We conducted a 4-year, prospective cohort study of children aged 0.5–17 years in 
Maliin 2008-2011. Exposures were haemoglobin S (HbS), HbC, α-thalassaemia, ABO blood 
groups, and glucose-6-phosphate dehydrogenase (G6PD)deficiency encoded by the X-linked A- 
*Corresponding author: Rick M Fairhurst MD PhD, Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, 
12735 Twinbrook Parkway, Room 3E-10A, Rockville, MD 20852, USA, Tel: 301-402-7393, Fax: 301-402-2201, 
rfairhurst@niaid.nih.gov. 
Contributors: TML-M, JMA, MPF, CAL, MD, and RMF contributed to study design. TML-M, SD, DK, JMA, MD, ASK, SASD, 
KT, MAK, and AD acquired data. TML-M, KM, WG, MPF, SMT, CAL, MD, and RMF analyzed and interpreted data. WG, MPF, 
SMT, and RMF performed statistical analysis. JMA, AD, SEM, and GST provided administrative or technical support. CAL, MD, and 
RMF supervised the study. MPF, SMT, and RMF wrote the report.
Conflicts of Interest: We declare that we have no conflicts of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Lancet Haematol. Author manuscript; available in PMC 2016 April 01.
Published in final edited form as:













allele. Primary and secondary outcomes were malaria incidence and parasite density. Incidence 
rate ratios (IRRs) were modeled with quasi-Poisson regression; parasite densities were analyzed 
with Generalized Estimating Equations.
Findings—We diagnosed 4091 malaria episodes in 1543 children over 2656 child-years of 
follow-up (cyfu). RBC variants were common: HbAS 14.2%, HbAC 6.7%, α-thalassaemia 28.4%, 
type O blood group 40.2%, and G6PD deficiency9.4% (boys) and 20.4% (girls). Malaria incidence 
was 1.54 episodes/cyfu, ranged from 2.78 at age 3 to 0.40 at age 16 years, was reduced 34% in 
HbAS vs HbAA children (adjusted IRR [aIRR] 0.66; 95% CI 0.59-0.75) and 49% in G6PD A-/A- 
vs A+/A+ girls (aIRR 0.51; 95% CI 0.29-0.90), but was increased 15% in HbAC children (aIRR 
1.15; 95% CI 1.01-1.32). Parasite density was reduced in HbAS vs HbAA children (median 
10,550 vs 15, 150 parasites/μL; p=0.0004). HbAS-associated reductions in malaria risk and 
parasite density were greatest in early childhood.
Interpretation—Individual and interactive impacts of HbAS, HbAC, and G6PD A-/A-on malaria 
risk and parasite density define clinical and cellular correlates of protection. Further identification 
of the molecular mechanisms of these protective effects may uncover novel targets for 
intervention.
Funding—Intramural Research Program, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health.
Introduction
Human red blood cell (RBC) variants are encoded by common genetic mutations that alter 
the structure of β-globins (haemoglobin S [HbS] and HbC), reduce the expression of α- or β-
globins (thalassaemias), or decrease the activity of essential enzymes (glucose-6-phosphate 
dehydrogenase [G6PD] deficiency). RBCs are further diversified by variation in surface 
antigens, including those that define the ABO, Duffy, and Rhesus blood groups.
This RBC diversity is partially driven by malaria caused by Plasmodium falciparum, which 
invades and matures within RBCs. To varying degrees, several RBC variants protect African 
children from life-threatening falciparum malaria. In clinical studies across multiple 
populations, sickle-cell trait (HbAS) and Hb Chomozygosity (HbCC) reduce this risk by 
70-90%; lesser reductions in risk are reported for Hb Cheterozygosity (HbAC), α-
thalassaemia, type O blood group, and G6PDdeficiency.1-4 These RBC variants confer 
protection by molecular mechanisms that remain under active investigation. Since these 
mechanisms reproducibly attenuate malaria pathogenesis, RBC variants constitute a 
naturally-occurring, in-vivo model of protection that can be used to investigate how to 
antagonize the detrimental effects of malaria parasites. In doing so, we may identify novel 
targets for preventive measures and adjunct therapies to reduce the estimated 437,000 
African children who die annually of falciparum malaria.5
To investigate the individual and interactive effects of RBC variants on the clinical 
epidemiology of falciparum malaria, we conducted the Kenieroba Innate Defense Study for 
Malaria (KIDS-Malaria). In this 4-year, prospective cohort study of 1543Malian children, 
we hypothesized that RBC variants – alone and in combination – differentially impact 
malaria risk and parasite densities. We tested these hypotheses using multivariate models 
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including each RBC variant and adjusting for age, sex, ethnicity, and year. Furthermore, we 
anticipated that the effects of RBC variants on these outcomes are modified by age, which is 
a strong surrogate for naturally-acquired immunity in malaria-hyperendemic areas of Africa.
Methods
Participants and setting
The KIDS-Malaria cohort comprises children enrolled in a prospective study between 2008 
and 2011 in the adjacent villages of Kenieroba, Fourda, and Bozokin in southern Mali, 
where P. falciparumis transmitted from June to December. Written informed consent was 
obtained from parents or guardians. The study was approved by the Ethics Committee of the 
Faculty of Medicine, Pharmacy, and Dentistry at the University of Bamako, and the 
Institutional Review Board at the National Institute of Allergy and Infectious Diseases 
(NIAID), US National Institutes of Health (NIH). The study is registered with 
Clinicaltrials.gov, number NCT00669084.
Beginning May 1, 2008, 1312 children were initially enrolled; children were subsequently 
enrolled into the cohort at age 6 months and removed at age 18 years (figure 1). Inclusion 
criteria were age 6 months to 17 years, lifelong residency in the three villages, and no plans 
to relocate before 2012; exclusion criteria were conditions that rendered the child unable to 
comply with the protocol (e.g., psychiatric disease) or posed unnecessary risks to the child 
(e.g., severe malnutrition). No sample size was predefined, although a priori power 
calculations were done assuming 1000 children would be included (appendix); we recruited 
as many children as possible without a formal census.
Outcome assessment
Case detection was passive; all parents were routinely encouraged to attend clinic for 
evaluation of childhood fever or other malaria symptoms. Outside our study clinic, health 
care options for evaluating fever and other malaria symptoms were essentially confined to 
visiting traditional healers, who worked closely with us to identify malaria patients and refer 
them to our study. Giemsa-stained thick blood films were prepared and examined on site, 
and asexual parasites were counted while also counting 300 leukocytes. Parasite density was 
defined as the number of parasites per 300 leukocytes multiplied by 25 (which assumes 7500 
leukocytes/μL in whole blood).
We defined falciparum malaria as axillary temperature >37.5°C (or history of fever within 
24 h) and a sexual P. falciparum parasitaemia, without other obvious causes of fever. We 
used World Health Organization criteria6 to define episodes as “major-severe” if the child 
had cerebral malaria, severe malarial anaemia, or respiratory distress; or “minor-severe” if 
the child had a parasite density >100,000 parasites/μL or needed parenteral therapy due to 
prostration, repetitive vomiting, or inability to tolerate oral therapy (appendix). Children 
without parasitemia were managed at the discretion of the study physician; these maneuvers 
and outcomes in children without malaria were not captured by our protocol. Children with 
malaria were treated with either oral artesunate-amodiaquine or parenteral quinine 
(appendix).
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At enrollment, all children provided a finger-prick blood sample for phenotyping and 
genotyping RBC variants. ABO blood groups were identified in the villages by agglutination 
assay (Cardinal Health, Dublin, OH); β-globin variants were determined at the University of 
Bamako by HPLC (D-10 instrument, Bio-Rad, Hercules, CA); and α-globin deletions (-
α3.7kb) and G6PD A- alleles were detected at the NIH using PCR-based assays, as 
described.7, 8
Statistical analyses
Time at risk for each study participant was quantified only during the malaria season, 
accounted for temporary or permanent censoring (appendix), and is expressed as child-years 
of follow-up (cyfu). We investigated malaria incidence rates using quasi-Poisson regression 
models and parasite densities using a log-transformed linear model with Generalized 
Estimating Equations (GEE). For each type of model, we tested covariates after adjusting for 
either age alone or a multivariate model. We investigated effect modification of HbAS on 
incidence and density by age by stratifying the models by age and re-calculating effect 
estimates. Absolute risk reductions (ARRs) of incidence in age-stratified groups by HbAS 
were computed using difference in incidence rates using Wald confidence intervals based on 
Poisson models, and events averted by HbAS were computed as Events avertedAS = 
IRAA×cyfuAS – Events observedAS. We assessed for effect modification of HbAS and HbAC 
on incidence and density by α-thalassaemia by stratifying the quasi-Poisson regression 
models and GEEs of HbAA, HbAS, and HbAC children by α+-thalassaemia (-α3.7/α α) and 
α0-thalassaemia (-α3.7/-α3.7) and re-calculating effect estimates. The overall epistasis effect 
was tested by F test for quasi-Poisson or score test for GEE for comparing the model with 
only β-globin and α-thalassaemia main effects to one that additionally included the 
interaction effect. Inferences for severe vs mild malaria used GEE logistic regression. 
Software and additional details are found in the appendix.
Role of the funding source
The sponsor had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all data in the study and 
the final responsibility for the decision to submit for publication.
Results
We successfully typed all five RBC variants for 1543 (97.3%) children, who thus constituted 
the analyzable population (table 1). Boys and girls were represented equally and the mean 
age at enrollment was 6 years, reflecting the recurring enrollment of newborns at age 6 
months. Most children were Malinke (86.3%);relatively few were Fulani (7.8%). The 
prevalences of RBC variants were: HbAS 14.2%, HbAC 6.7%, HbCC 0.1%, HbSC 0.7%, 
α+-thalassaemia 26.2%, α0-thalassaemia2.2%, type O blood group40.2%, and G6PD A- 
deficiency 9.4% in boys and 20.4% in girls. The gender balance, ethnic makeup, and 
prevalence of these RBC variants in our study population were broadly reflective of southern 
Malian populations.
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Over 2656 child-years of follow-up [cyfu; median years per child 2.01, interquartile range 
(IQR 1.15-2.24)], we recorded 4091 episodes of malaria: 3697 (90.4%) were mild and 
394(9.6%) were severe (either minor- or major-severe) (appendix). The overall incidence 
rate was 1.540 episodes/cyfu (table 2). This rate was lower in 2008 (1.188 episodes/cyfu) 
than in each of the next 3 years (1.691, 1.650, 1.611; p<0.0001), but did not differ 
significantly between sexes or villages. Ethnicity was associated with malaria risk in 
adjusted analyses: relative to Malinke children, incidence was higher in Bambara (adjusted 
incidence rate ratio [aIRR] 1.355; 95% CI 1.145-1.604; p=0.0004) and Dogon (aIRR 1.841; 
95% CI 1.173-2.891; p=0.0080), unchanged in Fulani, and lower in Sarakole children (aIRR 
0.571; 95% CI 0.403-0.809; p=0.0016).
In multivariate analyses that included RBC variants, age, ethnicity, and year, malaria 
incidence was reduced by 34% in HbAS (aIRR 0.662; 95% CI 0.586-0.747; p<0.0001) 
compared to HbAA children, and 49% in G6PD A-/A- girls (aIRR 0.513; 95% CI 
0.292-0.900; p=0.0200) relative to G6PD A+/A+ girls. Malaria risk was not significantly 
altered by α-thalassaemia or ABO blood groups, but was increased by 15% in HbAC 
children (aIRR 1.154; 95% CI 1.007-1.321; p=0.0390)compared to HbAA children. In 
models adjusted only for age, the IRR estimates were similar (table 2).
As reported in other studies,7, 9 we found suggestions that α-thalassaemia modified the 
HbAS effect on malaria risk. Relative to αα/αα children with HbAA, children with HbAS 
were protected from malaria (aIRR 0.662; 95% CI 0.572-0.767; p<0.0001), but there was no 
protection when -α3.7/-α3.7 was coinherited with HbAS (aIRR 1.133; 95% CI 0.473-2.72)
(figure 2A; appendix). Additionally, an increased risk for HbAC children with αα/αα was 
non-significantly increased even more for HbAC children with coinherited -α3.7/-α3.7 (figure 
2A; appendix). Despite these suggestions, the overall test that the β-globin effects change 
based on α-thalassaemia type is not significant (appendix, adjusted p=0.4821), likely due to 
the small numbers of HbAS or HbAC children with coinherited -α3.7/-α3.7. Nevertheless, the 
trend agrees with earlier reports, collectively suggesting a common mechanism by which α°-
thalassaemia may increase malaria risk when coinherited with β-globin variants.
Peak malaria incidence (2.78 episodes/cyfu) occurred at age 3 years (all ages in years except 
where indicated) and was nearly 7-fold higher (IRR 6.853; 95% CI 4.221-11.13) than at age 
17 (figure 3A; appendix). From age 4 to 13, malaria risk decreased 13.8% (95% CI 
11.6-16.0) per year. Age modified the HbAS effect on malaria incidence: relative to HbAA, 
HbAS conferred the greatest protection at age <1 (IRR 0.392; 95% CI 0.185-0.833; 
p=0.0155) with generally higher IRRs for older ages (figure 3B; appendix 6). A test of this 
trend (better HbS protection for younger children) based on the multivariate quasi-Poisson 
model was significant (p=0.02). From age <1 to 17, the IRR of HbAS relative to HbAA 
increased (i.e., protection decreased) on average 7.6% per year.
To identify age groups where HbAS protects children from malaria most effectively, we 
computed absolute risk reductions (ARRs) and the number of episodes averted by HbAS in 
each age group. All ARRs were significant through age 7 (figure 3C). Both measures were 
greatest at age 3, when an ARR of 1.372 (95% CI 0.688-2.05) was estimated to have 
prevented 38episodes in HbAS children. Because older age groups eventually acquire 
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protection irrespective of β-globin variant, 98.6% of the episodes averted by HbAS were at 
age ≤11 (figure 3C).
Overall, median parasite density at clinical presentation was 14,700 parasites/μL 
(IQR3850-30,100) (table 3). Of the covariates listed in table 3, only β-globin variant was 
significantly associated with parasite density. In analyses adjusted for age, ethnicity, and 
other RBC variants, densities were lower in HbAS vs HbAA children (median 10,550 vs 
15,150 parasites/μL; p=0.0004). We tested whether the effect of β-globin variant differed by 
α-thalassaemia genotype and found no significant epistasis (figure 2B; appendix).
Median parasite density peaked at age 2 (24,300 parasites/μL; IQR 9225-51,700) and 
declined substantially by age 17 (3100 parasites/μL; IQR 350-8600) (figure 3D; appendix). 
We used stratified analyses to investigate the interaction between HbAS and age on parasite 
density. At ages 1 through 5, parasite densities were significantly lower in HbAS than HbAA 
children (all p<0.04) (figure 3D; appendix); this effect was most pronounced at age 1, when 
median parasite density was 21,150 parasites/μL (IQR 7275-47,600) in HbAA and 4200 
parasites/μL (IQR 250-8250; p=0.005) in HbAS children. At ages >5, parasite densities were 
not significantly different between HbAA and HbAS children. In multivariate models that 
included ethnicity and other RBC variants as covariates, these age-stratified differences in 
parasite densities between HbAA and HbAS children remained significant (appendix), and 
a test on the age by HbS interaction from a multivariate model showed that the HbS effect 
was significantly more protective for younger ages (p<0.0001).
Of 4091 episodes of malaria, only 394 (9.6%) were treated as severe (appendix). Of these, 
38 (10%) were major-severe defined by cerebral malaria, severe malarial anaemia, or 
respiratory distress, 19 (5%) were characterized by parasite densities >100,000 parasites/μL, 
and 337 (85%) were minor-severe because they necessitated parenteral therapy owing to 
severe prostration, repetitive vomiting, or inability to tolerate oral therapy. The proportion of 
severe cases varied significantly between ages (p=0.002), and was highest at age <1 (17) and 
lowest at age 16 (3.3%) (appendix). This proportion was significantly lower in HbAS 
(5.4%) than HbAA (10.3%) children (age-adjusted p=0.002). Other RBC variants did not 
affect the distribution of mild and severe cases. Four severe cases died from: severe 
prostration; severe malarial anaemia; cerebral malaria, respiratory distress, and shock; and 
severe prostration and respiratory distress. These fatalities occurred in children aged 6 
months or 2 years who lacked β-globin mutations, α-globin deletions, and G6PD A-alleles.
Discussion
To investigate the effects of common RBC variants on malaria risk and parasite density, we 
enrolled 1543 children into a prospective cohort study over 4 years and recorded 4091 
malaria episodes in 2656cyfu in southern Mali. In this area of intense, seasonal P. falciparum 
transmission, 71.1% of children carried at least one RBC variant shown to reduce malaria 
risk in Africa in prior studies. HbAS most clearly conferred protection from malaria; 
moreover, age modified this effect, which was attenuated after early childhood and absent in 
teenagers. Similarly, HbAS reduced the density of parasites at clinical presentation, and did 
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so most substantially before age 5. Of the other RBC variants, only G6PD A-/A- in girls 
reduced malaria risk.
Relative to HbAA, HbAC increased malaria risk and α0-thalassaemiamay have augmented 
this risk. These findings are surprising because HbCC homozygotes experience substantial 
protection from severe malaria.10 While one case-control study found reduced malaria risk 
in HbAC children,10 two prior prospective studies in West Africa have suggested a small 
increase in risk.7, 11 This increased risk may sufficiently impair fitness in malaria-endemic 
areas to account for the very limited geographic distribution of HbC, despite the clear 
protection it affords to homozygotes, the mild clinical sequelae associated with it, and the 
greater age of HbC compared with HbS alleles.12 The molecular pathology of HbAC on 
RBCs is minimal, manifesting as slightly reduced RBC lifespan, mild anaemia (with normal 
reticulocytaemia),13 and increased mean corpuscular haemoglobin concentration.14 In-vitro 
experiments indicate that HbAC RBCs support normal invasion and parasite maturation15, 16 
but reduce the expression of parasite cytoadherence proteins on the RBC surface;17 this 
latter finding, also present in HbAS RBCs,18 suggests a common mechanism of protection 
where in these β-globin variants attenuate cytoadherence and modulate innate immune 
activation.19 Our finding of increased malaria risk in HbAC children suggests that these 
cellular phenotypes may not correlate strongly with mild disease risk, or may be modified by 
other factors in vivo.
As expected based on prior prospective studies (reviewed in1), HbAS reduced malaria risk 
by 34% relative to HbAA. Additionally, this protection was unapparent when HbAS was 
coinherited with α0-thalassaemia. Although the interaction between variants was not 
statistically significant, this observation supports epistasis, or effect modification, by α-
thalassaemia on malaria risk. Epistasis has been reported in earlier prospective studies,7, 9, 11 
likely due to reduced production of HbS in HbAS RBCs that harbor α-globin deletions,20 
and in an in-vitro study21 showing that α-thalassaemia antagonizes HbAS-mediated 
reductions in cytoadherence. This finding may explain the clinical observations that α-
thalassaemia exerts negative epistatic effects on HbAS-mediated protection from malaria, as 
reported in prior studies7, 9 and suggested by our data.
Age significantly modified malaria risk, which peaked at age 3 and remained significantly 
elevated through age 13 (relative to age 17). We also studied age modification of the HbAS 
effect on risk. Our study shows that protection of HbAS relative to HbAA children was 
significantly better at younger ages with respect to both malaria incidence (p=0.02) and 
parasite density (p<0.0001). This suggests that the biological effects of HbAS on P. 
falciparum progressively decline with advancing age in early childhood. This adds to a 
previousstudy22 that found non-significant trends for age-modifying effects on HbS 
protection. Several lines of evidence support the notion that naturally-acquired immunity is 
partly dependent on intrinsic age-related factors that are independent of parasite exposure 
(reviewed in 23).
Of all the RBC traits we investigated, only HbAS was associated with reduced parasite 
densities at the time of presentation. Whether this reduction is clinically significant is not 
known, but elucidating the mechanism of this effect may provide insights into HbAS-
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mediated protection from mild and severe malaria. Intriguingly, this effect was significant 
only through age 5, after which densities were comparable between HbAS and HbAA 
children. Infected HbAS RBCs demonstrate reduced cytoadherence in vitro;18 this 
phenotype, which may be enhanced in vivo by RBC sickling in relatively hypoxic 
environments of post-capillary venules and the cytoadherence-blocking effects of naturally-
acquired IgG responses, may contribute to the reduced parasite densities we observed in 
HbAS children. The coincident reduction in malaria risk attributed to HbAS before age 5 
supports the premise that reduced parasite density contributes directly to this protection. 
Indeed, several in-vitro studies have reported that HbAS impairs parasite growth because of 
reduced oxygen tension24, 25 or the action of RBC microRNAs,26 and these phenomena may 
limit parasite propagation in vivo. However, it seems increasingly clear that attenuation of 
parasite growth alone is insufficient to prevent disease.27 Also, although α0-
thalassaemiaappeared to antagonize HbAS protection from malaria, it did not lessen the 
reduction in parasite density in HbAS children. It therefore seems unlikely that HbAS 
protects principally by suppressing parasite density. Additional hypotheses are that HbAS 
modulates the strength of cytoadherence18 or intensity of innate immune responses, enabling 
children to tolerate parasitemia without developing symptoms.28
HbAS also reduced the proportion of malaria cases with severe manifestations. As often 
seen in cohort studies, classic manifestations of life-threatening malaria syndromes – 
including cerebral malaria, severe malarial anaemia, and respiratory distress – were 
uncommon, and most cases required treatment as severe due to an inability to tolerate oral 
therapy. Nevertheless, HbAS reduced these “minor-severe” syndromes as well, indicating 
that it generally attenuates the pathophysiology of malaria. The mechanisms of this effect 
require further exploration as a basis for preventive or therapeutic intervention.
In our cohort, neither α-thalassaemias, ABO blood groups, nor G6PD A- hetero- or 
hemizygosities protected from malaria. Prior studies have reported that α-thalassaemia 
protects from severe but not mild malaria (reviewed in 1) and that type O blood group 
weakly protects from severe malaria.29 Given the high prevalence of these traits in our 
cohort, our study was well-powered to detect appreciable differences in risk. Based on our 
data, these protective impacts appear limited to severe disease and are insufficient to 
substantially prevent mild malaria.
To our knowledge, this study is the first to report that G6PD A-/A- girls are protected from 
malaria: relative to G6PD A+/A+ girls, malaria risk was slightly higher for A+/A-(aIRR 
1.124) but significantly lower for A-/A-girls (aIRR 0.513). G6PD A-/A- girls also had lower 
parasite densities than A+/A- girls, suggesting a significant biological impact of a uniform 
population of G6PD-deficient RBCs within a host. We interpret these data with some 
caution, however, as they derive from 17 episodes in 13 G6PD A-/A- girls, and are not 
corroborated by a similar trend in data from G6PD A+/A- girls. Both the overlapping 
geographical distributions of G6PD deficiency and falciparum malaria, as well as in vitro 
experiments,30, 31 suggest that G6PD deficiency confers some protection; however, prior 
clinical studies of G6PD deficiency and malaria risk are inconsistent, reporting increased 
disease risk in heterozygous girls,32 decreased disease risk in deficient girls,33 decreased 
severe disease risk in hemizygous boys,8 and an absence of effect.34 Our study benefits from 
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a prospective design, prolonged follow-up period, and relatively high prevalence of A-/A- 
homozygotes; also, the absence of alternative alleles encoding the A- form of 
G6PDdeficiency in Mali35 enabled us to accurately assign G6PD status to children based 
only on the 202A mutation, thus avoiding misclassifications that have bedeviled other 
studies in western Africa.36 Despite the protection in G6PD A-/A-girls, G6PD A- boys were 
clearly not protected, perhaps due to the more marked phenotypic deficiency in hemizygotes 
than homozygotes in Africa.35 Future work is needed to explore the relative impacts of 
phenotypic and genotypic G6PD deficiency on falciparum malaria in high-transmission 
settings.
Finally, ethnicity was associated with malaria risk independent of other measured traits. 
Surprisingly, Fulani children were not protected from malaria, though they had slightly 
lower parasite densities than Malinke children in adjusted analyses. Prior studies have 
reported lower parasite prevalences in Fulani (relative to Mossi in Burkina Faso37 and 
Dogon in Mali38), which was subsequently correlated with deficits of regulatory T cells 
(relative to Mossi39) and enhanced early interferon-γ production in response to parasite 
antigens (relative to Dogon40). Our contradictory findings may result from two key 
differences: our designation of Malinke children as the comparator group, and our use of a 
prospective study design that measured malaria incidence instead of parasite prevalence. 
Interestingly, malaria risk differed significantly between Malinke, Bambara, and Sarakole 
children despite all three groups belonging to the larger Mande ethnic group, which 
population genetics analyses have distinguished from other groups in the region.41
Our study has several potential limitations. It is possible that we did not capture all malaria 
episodes, but other options for health care are limited in the study area, and it is unlikely that 
the incidence of missed episodes would vary between participants with different RBC 
variants. We enrolled few children with the putatively protective variants of homozygous 
HbC, G6PD A-, or α-thalassemia, limiting our ability to quantify their effects on malaria. 
Since we provided rapid access to effective therapy, we cannot directly estimate the impact 
of these mutations on survival in malaria-endemic areas. Finally, unmeasured covariates – 
including bed net use, socioeconomic status, co-infections, or heretofore unknown mediators 
of protection – could have biased our protective estimates.
Our prospective study of children carrying a high prevalence of RBC variants in an area of 
intense, seasonal P. falciparum transmission clearly defines the clinical impact of these traits 
on malaria risk and parasite density. Investigating natural patterns of disease susceptibility in 
endemic areas may uncover mechanisms of pathogenesis that can be targeted to prevent and 
treat malaria.
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Research in context panel
Evidence before this study
We previously conducted a systematic review and meta-analysis of the influence of 
haemoglobinopathies on the risks of severe and mild malaria on September 9, 
2011[Taylor SM et al. Lancet Infect Dis 2012; 12(6): 457-68]. We repeated the search in 
PubMed using identical search criteria on January 12, 2015; this search returned 949 
papers, of which we reviewed the full texts of 15, of which seven contained relevant 
information. Four of these papers [Timmann C et al. Nature 2012; 489(7416): 443-6; 
Atkinson SH et al. Blood 2014; 123(13): 2008-16; Manjurano A et al. Plos One 2012; 
7(10): e47463; Toure O et al. Plos One 2012; 7(9): e43987] confirmed that HbAS 
substantially reduces the risk of severe falciparum malaria (by 88-97%), and other studies 
confirmed that HbAS mildly reduces the risk of mild malaria. The risk of severe malaria 
was also decreased by heterozygous α-thalassaemia, heterozygous G6PDdeficiency in 
girls, and type O blood group. This search also returned a meta-analysis of case-control 
studies of the impact of ABO blood group type on malaria [Panda AK et al. Malar J 
2011; 10: 309]. This meta-analysis of six studies reported that type O blood group 
reduces the risk of severe malaria by 50%. Finally, we searched PubMed on January 12, 
2015 using the search terms (“malaria” [Title/Abstract] OR “malaria/blood” [MAJR] OR 
“malaria/genetics” [MeSH Terms]) AND (“G6PD” [Title/Abstract] OR “glucose-6-
phosphate-dehydrogenase” [Title/Abstract] OR “glucose phosphate dehydrogenase 
deficiency/genetics” [MeSH Terms] OR “glucose phosphate dehydrogenase deficiency/
blood” [MeSH Terms]). This search returned 572 papers. There exists no consensus on 
the influence of G6PD deficiency on malaria; investigations of this relationship have been 
complicated by the genotypic and phenotypic diversity of G6PD deficiency, diverse 
parasite epidemiology, and varied study designs and control selection. There remains a 
paucity of prospective cohort studies of G6PD deficiency on falciparum malaria.
Added value of this study
HbAS reduces both the risk of falciparum malaria and the density of parasites at the time 
of clinical presentation with malaria; the greatest degree of protection is conferred in the 
early years of childhood, when malaria incidence in children overall is highest and before 
immunity to clinical disease is acquired. Homozygous G6PD-deficiency encoded by the 
X-linked A- allele reduced the risk of malaria in girls, while HbAC increased the risk of 
malaria in children.
Implications of all the available evidence
By reducing the risk of falciparum malaria, suppressing parasite density, or both, RBC 
variants offer models of attenuated pathogenesis. These models can be exploited by 
future cellular, molecular, and immunologic studies to define mechanisms by which these 
RBC variants counteract the detrimental effects of P. falciparum parasites. Defining these 
mechanisms will provide targets for future antiparasitic or adjunct therapies for children 
with falciparum malaria.
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Child enrollment and follow-up. We enrolled a total of 1586 children in the KIDS-Malaria 
cohort: 1312 children during initial enrollment in May 2008, and 274 who aged into the 
study in subsequent years. Of these 1586 children, 1335 (84.2%) completed follow-up 
through the end of the 2011 transmission season. The major reasons for 251 children not 
completing follow-up were relocation (47.0%), attaining 18 years of age (24.3%), parental 
withdrawal (20.7%), and death from any cause (8.0%).
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Modification of HbAS and HbAC effects on malaria incidence (A) and parasite density (B) 
by α-thalassaemia. A. Diamonds and bars indicate incidence rate ratios adjusted for age 
(relative to HbAA, αα/αα children)and 95% confidence intervals (left y-axis). Squares 
indicate crude incidence rates (right y-axis).cyfu, child-years of follow-up. B. Diamonds and 
bars indicate median parasite density and interquartile range.
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Impact of age on (A) malaria incidence in all children, (B) relative malaria protection by 
HbAS, (C) absolute malaria risk in HbAS children, and (D) relative reduction in parasite 
density by HbAS. A. Diamonds and bars indicate incidence rate ratios (IRRs) relative to age 
17 and 95% confidence intervals (CI; left y-axis). Line indicates incidence rate (right y-
axis). B. Diamonds and bars indicate IRRs in HbAS relative to HbAA children and 95% CIs 
(left y-axis). Lines indicate incidence rate in HbAA (dotted) and HbAS (dashed) children. C. 
Diamonds and bars indicate absolute risk reductions (ARRs) in HbAS children and 95% CIs 
(left y-axis). Gray bars indicate the estimated number of episodes averted by HbAS. 
Asterisks indicate years with negative ARR and therefore negative averted cases. D. Lines 
indicate median parasite densities in HbAA (dotted) and HbAS (dashed) children. Gray area 
indicates interquartile ranges for parasite densities in all children irrespective of β-globin 
variant. Asterisks indicate ages at which parasite densities were significantly different 
(p<0.05) between HbAA and HbAS children. In all panels, age=0 indicates age<1 year.
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Table 1
Characteristics of 1543 child participants
Village, n (%)
 Kenieroba 1178 (76.3)
 Fourda 180 (11.7)
 Bozokin 185 (12.0)
Ethnicity*, n (%)
 Malinke 1332 (86.3)
 Fulani 121 (7.8)
 Bambara 62 (4.0)
 Sarakole 24 (1.6)




Age at enrollment, y, mean (SD) 6 (5.1)
β-globin variant, n (%)
 HbAA 1206 (78.2)
 HbAS 220 (14.2)
 HbAC 103 (6.7)
 HbCC 1 (0.1)
 HbSC 11 (0.7)
 HbSS 2 (0.1)
α-globin variant, n (%)
 Normal (αα/αα) 1105 (71.6)
 α+-thalassaemia (-α3.7/αα) 404 (26.2)
  α0-thalassaemia (-α3.7/-α3.7) 34 (2.2)
Blood group, n (%)
 A 465 (30.1)
 B 334 (21.7)
 AB 123 (8.0)
 O 621 (40.2)
G6PD A- genotype, n (%)
Boys
 Normal 695 (45.0)
 A- hemizygotes 72 (4.7)
Girls
 Normal 618 (40.1)
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 A-/A+ heterozygotes 145 (9.4)
 A-/A- homozygotes 13 (0.8)
*Self-reported.
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